14 March 2022
Instem plc
("Instem" or "the Company")
Exercise of Options, Issue of Equity and Total Voting Rights
Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, announces that it was notified on 14 March 2022 that certain employees of the Company exercised share options ("Share Options") over, in aggregate, 90,000 ordinary shares of 10 pence each in the Company ("Ordinary Shares").
Issue of Equity and Admission
Application will be made to the London Stock Exchange for the admission of the 90,000 new Ordinary Shares to trading on AIM ("New Ordinary Shares"). Admission is expected to take place at 8.00 a.m. on 18 March 2022.
Total voting rights
Following the issue and allotment of the above New Ordinary Shares, the Company's issued share capital comprises 22,379,856 Ordinary Shares. The Company does not hold any Ordinary Shares in treasury. Therefore the total number of voting rights in the Company is 22,379,856.
The figure of 22,379,856 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change of their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
For further information, please contact:
| Instem plc | via Walbrook |
| | |
| | |
|
Singer Capital Markets (Nominated Adviser & Broker) |
+44 (0) 20 7496 3000 |
| Peter Steel Rachel Hayes Alex Bond | |
| | |
|
Stifel Nicolaus Europe Limited (Joint Broker) |
+44 (0) 20 7710 7600 |
| Ben Maddison | |
| Alex Price
| |
|
Walbrook Financial PR |
+44 (0) 20 7933 8780 |
| Tom Cooper | instem@walbrookpr.com |
| Nick Rome
| |
About Instem
Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management, Regulatory Submissions, Clinical Trial Acceleration, and Informatics-based Insight Generation.
Instem solutions are in use by over 700 customers worldwide, including all of the largest 25 pharmaceutical companies, enabling clients to bring life enhancing products to market faster. Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.
Instem products and services address aspects of the entire drug development value chain, from discovery through to market launch. Management estimate that over 50% of all drugs on the market have been through some part of Instem's platform during their development.
To learn more about Instem solutions and its mission, please visit www.instem.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
